Release date: 2024-08-06 17:24:03 Article From: Lucius Laos Recommended: 133
Capmatinib inhibits the growth of cancer cells caused by specific genetic variants, i.e., MET exon 14 skipping or MET amplification. These genetic variants are common in tumors such as lung cancer.
At present, capmatinib has been marketed in China, but it has not been included in the scope of medical insurance reimbursement in China, and patients need to purchase it at their own expense. The latest price of capmatinib is detailed below.
The price of capmatinib (200mg*60 tablets) produced by Lucius Pharmaceutical in Laos is about 2,650 yuan per box, while the price of the same specification product (200mg*56 tablets) of Bangladesh Everest Pharmaceutical is slightly higher, about 3,600 yuan per box.
Novartis' Rahika brand capmatinib (200mg*60 tablets) is priced at about 12,500 yuan. Switzerland Novartis Pharmaceutical's capmatinib provides two dose specifications (200mg60 capsules and 150mg*60 capsules), and the price of the combination is about 31250 yuan per box.
The above prices are indicative prices and may fluctuate due to a number of factors at the time of purchase. The instability of drug prices is mainly due to the relationship between market supply and demand, exchange rate changes, import tariff adjustments, changes in production costs, and pricing strategies of different sales channels. The scarcity of medicines, the capacity constraints of manufacturers, and policy guidance may also have an impact on prices.
Lucius Pharmaceuticals adheres to internationally recognized quality management system standards and puts patient health and safety first. A complete set of quality management framework has been established, which covers every link from raw material procurement, production process control, finished product storage to sales and distribution, ensuring that all operations are meticulously monitored and inspected.
Through continuous optimization of manufacturing processes and technological innovation, Lucius Pharma is committed to ensuring that high quality standards are met and maintained in every batch of pharmaceutical products.
[Warm tips] When purchasing capmatinib, it is recommended that patients consult a doctor or pharmacist in advance to understand the latest market price information and make a reasonable choice according to their own economic situation and treatment needs. Attention should also be paid to choosing formal channels to purchase to ensure the quality of drugs.
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:2012024-09-07
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended:1582025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended:1562025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended:1712024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended:1612024-24-12
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use in combina···【more】
Recommended:1462024-17-12
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-CD19 chimeric antigen···【more】
Recommended:1052024-13-12
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHM···【more】
Recommended:2482024-26-08
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: